Acrivon Therapeutics Statistics
Total Valuation
ACRV has a market cap or net worth of $226.33 million. The enterprise value is $120.38 million.
| Market Cap | 226.33M |
| Enterprise Value | 120.38M |
Important Dates
The next estimated earnings date is Friday, August 9, 2024, before market open.
| Earnings Date | Aug 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ACRV has 30.88 million shares outstanding. The number of shares has increased by 3.06% in one year.
| Shares Outstanding | 30.88M |
| Shares Change (YoY) | +3.06% |
| Shares Change (QoQ) | +1.13% |
| Owned by Insiders (%) | 22.92% |
| Owned by Institutions (%) | 69.45% |
| Float | 12.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.10 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.40, with a Debt / Equity ratio of 0.04.
| Current Ratio | 12.40 |
| Quick Ratio | n/a |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -49.70% and return on invested capital (ROIC) is -62.60%.
| Return on Equity (ROE) | -49.70% |
| Return on Assets (ROA) | -45.00% |
| Return on Capital (ROIC) | -62.60% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.05M |
| Employee Count | 61 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.34% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -44.34% |
| 50-Day Moving Average | 7.41 |
| 200-Day Moving Average | 6.07 |
| Relative Strength Index (RSI) | 52.20 |
| Average Volume (20 Days) | 139,638 |
Short Selling Information
The latest short interest is 1.15 million, so 3.71% of the outstanding shares have been sold short.
| Short Interest | 1.15M |
| Short Previous Month | 1.04M |
| Short % of Shares Out | 3.71% |
| Short % of Float | 9.52% |
| Short Ratio (days to cover) | 8.74 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -70.38M |
| Pretax Income | -64.12M |
| Net Income | -64.12M |
| EBITDA | -62.67M |
| EBIT | -64.12M |
| Earnings Per Share (EPS) | -$2.89 |
Balance Sheet
The company has $110.39 million in cash and $4.45 million in debt, giving a net cash position of $105.95 million or $3.43 per share.
| Cash & Cash Equivalents | 110.39M |
| Total Debt | 4.45M |
| Net Cash | 105.95M |
| Net Cash Per Share | $3.43 |
| Equity (Book Value) | 107.98M |
| Book Value Per Share | 3.50 |
| Working Capital | 103.10M |
Cash Flow
In the last 12 months, operating cash flow was -$48.37 million and capital expenditures -$2.08 million, giving a free cash flow of -$50.45 million.
| Operating Cash Flow | -48.37M |
| Capital Expenditures | -2.08M |
| Free Cash Flow | -50.45M |
| FCF Per Share | -$2.23 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ACRV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.06% |
| Shareholder Yield | -3.06% |
| Earnings Yield | -28.33% |
| FCF Yield | -22.29% |
Analyst Forecast
The average price target for ACRV is $24.00, which is 227.42% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $24.00 |
| Price Target Difference | 227.42% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | 2.23% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |